Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations
Year: 2018
Type: article
Study design: Observational Study
Abstract: -positive cases exposed to platinum chemotherapy or PARP inhibition, the prevalence of reversion mutations was 40%. This report documents the frequency of reversion mutations in a large cohort of prostate cancer patients carrying of BRCA mutations. It also shows the potential utility of ctDNA analyses for early detection of reversion mutation driving tumor resistance.
Source: JCO Precision Oncology
DOI: 10.1200/po.17.00176
Authors: Benedito A. Carneiro, Katharine Ann Collier, Rebecca J. Nagy, Sahithi Pamarthy, Vinay Sagar, Stephen Fairclough, Justin Odegaard, Richard B. Lanman, Ricardo Costa, Timothy Taxter, Timothy M. Kuzel, Alice Fan, Young Kwang Chae, Massimo Cristofanilli, Maha H. Hussain, Sarki A. Abdulkadir, Francis J. Giles
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: National Cancer Institute
OpenAlex ID: W2786409274